Dramatic Response to Lorlatinib in a Heavily Pretreated Lung Adenocarcinoma Patient Harboring G1202R Mutation and a Synchronous Novel R1192P ALK Point Mutation

Authors :: Rita Chiari
Biagio Ricciuti
Giulio Metro
Annamaria Siggillino
Andrea De Giglio
Sara Baglivo
Vienna Ludovini
Source :: Journal of Thoracic Oncology. 13:e145-e147
Publication Year :: 2018
Publisher :: Elsevier BV, 2018.

Subjects :: 0301 basic medicine
Pulmonary and Respiratory Medicine
Lung
business.industry
Point mutation
medicine.disease
Lorlatinib
03 medical and health sciences
030104 developmental biology
0302 clinical medicine
medicine.anatomical_structure
Oncology
030220 oncology & carcinogenesis
Mutation (genetic algorithm)
Cancer research
medicine
Adenocarcinoma
business

Full Text Access

Tools